Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy

BACKGROUND: The long-term prognosis of patients with hepatocellular carcinoma (HCC) after surgery remains far from satisfactory, especially in patients with microvascular invasion (MVI). This study aimed to evaluate the potential survival benefit from adjuvant lenvatinib for patients with HCC and MV...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Mu-Gen, Liu, Si-Yu, Lu, Wen-Feng, Liang, Lei, Ye, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278397/
https://www.ncbi.nlm.nih.gov/pubmed/37342206
http://dx.doi.org/10.1177/11795549231180351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278397/
https://www.ncbi.nlm.nih.gov/pubmed/37342206
http://dx.doi.org/10.1177/11795549231180351

Ejemplares similares